Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan

We compared a standard antihypertensive losartan treatment with a pharmacogenomics-guided rostafuroxin treatment in never-treated Caucasian and Chinese patients with primary hypertension. Rostafuroxin is a digitoxigenin derivative that selectively disrupts the binding to the cSrc-SH2 domain of mutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Citterio, Lorena, Bianchi, Giuseppe, Scioli, Giuseppe A., Glorioso, Nicola, Bigazzi, Roberto, Cusi, Daniele, Staessen, Jan A., Cavuto, Silvio, Ferrandi, Mara, Lanzani, Chiara, Li, Xiaoyi, Lau, Lit-Fui, Chiang, Chern-En, Wang, Tzung-Dau, Wang, Kang-Ling, Ferrari, Patrizia, Manunta, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159753/
https://www.ncbi.nlm.nih.gov/pubmed/33649520
http://dx.doi.org/10.1038/s41397-021-00214-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159753/
https://www.ncbi.nlm.nih.gov/pubmed/33649520
http://dx.doi.org/10.1038/s41397-021-00214-y

Ejemplares similares